Based on scientific research results performed by HiPep Laboratories during the last decade a new company, PIPLS Pharma Inc., was founded on Aug . 5, 2016, in Kyoto. Fortunately the new company receives investments with the “exit doe products” in the business model. PIPLS is an abbreviation of “Peptides containing Imidazole and Pyrrole as building blocks- Large scale Syntheses“. PIPLS Pharma focuses on GMP production of high quality peptide derivatives, especially peptide conjugates and PIPA (peptides consisting of pyrrole and imidazole as major building unites) for clinical applications. PIPA is a novel drugs with novel action mechanisms such as gene controls. Hence, HiPep laboratories is a research company having the enormous know-how concerning combinatorial compound libraries and proteins & peptides science, especially production, separation and characterization has been generated several concepts, PepTenChip®, on bead cyclic peptides, Peptide-Vehicle which involved delivery system for drugs. HiPep continues further development for practical applications of the novel Biochip system, PepTenChip®. PIPLS Pharma has been founded as spin off from HiPep for production of API from HiPep in Aug. 2016. PIPA can bind to specific nucleotide sequences in the minor groove of double-helical DNA with high affinity and specificity, suggesting that PIPA blocks binding of transcription factors inhibiting gene expression, thus PIPA can be applied to gene- therapy. Additionally, PIPA can be also used for specific double strand DNA-visualization for diagnostics. Advantages of PIPA are: stabilities (nuclease resistant); entering into cell nucleus without any DDS-technologies; siRNA causes knockdown of genes and side effects are unneglectable; PNA is toxic. Until now no-toxicities of PIPA have been found in animal experiments. PIPA is difficult to prepare and industrial production has not yet been reported in world wide. Focusing on drug production industrial production system has been successfully established by Dr. Nokihara supported by two national grants of Japan (2013-2014 JST and 2014-2015 NEDO) based on Dr. Nokihara’s expertise. Until 2016 a ” Large Scale Syntheses System for PIPA, PIPLS System” has been completed. Industrial scale GMP-products are indispensable for clinical trial as well as for FDA-approval. In addition to PIPA, GMP grade of numerous peptides can be produced, angiogenic peptides (AGP) can be also produced for regenerative medicine, of which patent enforcement by PIPLS. Initial investment was ca. 3 million USD by Bio-division of Alpha Holdings. Since PIPLS Pharma will not carrying out researches in drug discovery but production of active pharmaceutical ingredients, relatively shorter term M&A or IPO can be expected. The location of GMP-facility was found in Gumpo-city near Seoul, Korea. Corporate Profiles PIPA as a DNA-probes 1. Alternative gene silencer other than siRNA or PNA. 2. Stable in cells or bodies because of nuclease resistance. 3. Specifically binds to the target double strand DNA. 4. Enter into cell nucleus without any DDS. 5. Flexible Design against any gene. 6. No-toxicities have been found in animal experiments. 7. Target diseases: not possible by small molecules or antibodies PIPA can be used for therapies for gene-control with different mechanisms against conventional methods. Recently, HPTH59 was commercialized as the optimal probe for telomere staining, which is not affected by nuclease, enters into cell nuclei without any delivery systems and allows high throughput quantitative measurement of telomere length with less disruptive process. Comparing to the other methods, such as telomerase, Southern blotting and/or PNA- fluorescence in situ hybridization method, the probe HPTH59 can offer simple with lower background staining. Advantages of PIPA focusing on novel drugs http://pipls.hipep.com/ [email protected] 1/2 PIPLS-O001E